Abstract 111P
Background
Immunohistochemistry (IHC)/in situ hybridization (ISH) are widely used methods in many pathology laboratories to assess human epidermal growth factor receptor 2 (HER2) status in gastric cancer (GC) patients. Nowadays, next generation sequencing (NGS) technologies are adopted to precisely predict absolute gene amplification levels. However, these tissue-based tests are suffering from intratumoral heterogeneity and inter-laboratory technical biases.
Methods
We set up a novel probe-based Absolute Q digital PCR assays for quantitative measurement of HER2 amplification using the formalin-fixed paraffin embedded (FFPE) tissue samples and the results were compared with IHC/ISH and NGS results in 184 gastric adenocarcinoma samples. HER2 amplifications were determined with HER2 TaqMan® probe hydrolysis assays within exon 22 and was multiplexed by the ratios of HER2 copy number (CN) to reference gene CN (HER2/RNaseP ratio).
Results
With digital PCR, the median HER2 CN were 1.79 copies/μL (ranged from 0.02 to 48.87 copies/μL). With NGS, HER2 amplifications were detected in 28 cases (15.2%). By IHC, HER2 positive (3+) was found in 25 cases (13.6%) and equivocal (2+) cases were observed in 15 cases (8.2%), in which ISH conformed amplifications in 13 cases. The concordance rate between IHC (3+ or 2+ and HER2 amplified) and NGS was 71.3%. In HER2-amplified cases by NGS, the median CN measured with digital PCR were 9.7 copies/μL (ranged from 1.95 to 48.87 copies/μL). In statistical analyses, Pearson correlation coefficients between NGS and digital PCR was 0.916, suggesting strong correlation. Given HER2 amplification by NGS as the standard reference, digital PCR predicted HER2 amplification with a 98.7% specificity, 92.9% sensitivity, 92.9% positive predictive value, and 98.7% negative predictive value. The AUC values for predicting HER2 amplification by digital PCR were 0.989.
Conclusions
With newly designed novel probes, digital PCR accurately measured HER2 CN with high sensitivity and specificity.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The Ministry of Health & Welfare, Republic of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract